Companies:
53,025
Total Market Cap:
168995621325007.08
Global Rank
#51522
Country Rank
#3034
Market Cap
162,634.12
Price
0.242
Change (%)
0.00%
Volume
1,000
Mydecine Innovations Group's latest marketcap:
162,634.12
As of 02/03/2026, Mydecine Innovations Group's market capitalization has reached $162,634.12. According to our data, Mydecine Innovations Group is the 51522th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 162,634.12 |
| Revenue (ttm) | 0 |
| Net Income (ttm) | 1.67 M |
| Shares Out | 0 |
| EPS (ttm) | 1.36 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 03/31/2026 |
Market Cap Chart
Data Updated: 02/03/2026
Mydecine Innovations Group's yearly market capitalization.
Mydecine Innovations Group has seen its market value drop from C$1.7 M to C$222,207 since 2015, representing a total decrease of 86.94% and an annual compound decline rate (CAGR) of 18.19%.
| Date | Market Cap(C$) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 02/03/2026 | C$222,207 | $162,634.12 | -40% | 51522 |
| 12/22/2025 | C$370,354 | $264,633.08 | 48.86% | 45456 |
| 12/31/2024 | C$248,797 | $172,864.16 | -75.95% | 45236 |
| 12/29/2023 | C$1.03 M | $780,343.82 | -86.33% | 42943 |
| 12/30/2022 | C$7.57 M | $5.58 M | -79.2% | 37955 |
| 12/31/2021 | C$36.39 M | $28.77 M | -53.83% | 30836 |
| 12/31/2020 | C$78.82 M | $0 | 1480.26% | 23464 |
| 12/31/2019 | C$4.99 M | $3.84 M | -73.1% | 31269 |
| 12/31/2018 | C$18.54 M | $13.58 M | -55.8% | 26853 |
| 12/29/2017 | C$41.94 M | $33.32 M | 228.66% | 23489 |
Company Profile
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc. is a biotechnology company dedicated to the research, development, and commercialization of psilocybin-based treatments for mental health conditions.
Key Focus Areas
- Treatment of nicotine addiction
- Post-traumatic stress disorder (PTSD) management
Product Pipeline
- MYCO-005 – Lead drug candidate
- MYCO-006 & MYCO-007 – Additional compounds in development
Strategic Partnerships
The company collaborates with Applied Pharmaceutical Innovation for drug discovery and R&D on empathogenic and entactogenic compounds.
Corporate Background
- Formerly known as NewLeaf Brands Inc.
- Renamed to Mydecine Innovations Group Inc. in June 2020
- Founded in 2013
- Headquartered in Vancouver, Canada
Frequently Asked Questions
-
What is Mydecine Innovations Group's (CSE-MYCO) current market cap?As of 02/03/2026, Mydecine Innovations Group (including the parent company, if applicable) has an estimated market capitalization of $162,634.12 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Mydecine Innovations Group (CSE-MYCO) rank globally by market cap?Mydecine Innovations Group global market capitalization ranking is approximately 51522 as of 02/03/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.